GigaGen: GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment
GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed at treating HBV. The post GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment appeared first on Clinical Trials Arena.
Read full article »
GigaGen is a biotechnology company that develops and commercializes single-cell technology-based antibody drugs to treat infectious diseases.
Read more